Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors

European Journal of Heart Failure

Volumn 9, Issue 2, 2007, Pages 197-201

  Meune, Christophe ^a   Wahbi, Karim ^a   Fulla, Yvonne ^a   Cohen Solal, Alain ^b   Duboc, Denis ^a   Mahé, Isabelle ^c   Simoneau, Guy ^c   Bergmann, Jean François ^c   Weber, Simon ^a   Mouly, Stéphane ^c  

^a Institut Cochin   (France)

^b BEAUJON HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Aspirin; Brain natriuretic peptide; Clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; PROSTAGL; RAMIPRIL; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT CONTRAINDICATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ASPIRIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSTAGLANDINS; TICLOPIDINE;

EID: 33847793850     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.06.003     Document Type: Article

References (35)

1. Benedict C.R., Johnstone D.E., Weiner D.H., Bourassa M.G., Bittner V., Kay R., et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 23 (1994) 1410-1420
2. Maeda K., Tsutamoto T., Wada A., Malbuchi N., Hayashi M., Tsutui T., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587-1593
3. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., et al., Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial. Circulation 106 (2002) 2254-2258
4. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al., for the task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
5. Witherow F.N., Helmy A., Webb D.J., Fox K.A.A., and Newby D.E. Bradykinin contributes to the vasodilatator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104 (2001) 2177-2181
6. Townend J.N., Doran J., Lote C., and Davies M.K. Peripheral hemodynamics effect of inhibition of prostaglandin synthesis in congestive heart failure and interaction with captopril. Br Heart J 73 (1995) 734-741
7. Meune C., Mourad J.J., Bergmann J.F., and Spaulding C. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rational and clinical relevance. J Renin Angiotensin Aldosterone Syst 4 (2003) 149-154
8. Meune C., Mahé I., Mourad J.J., Cohen-Solal A., Levy B., Kevorkian J.P., et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail 5 (2003) 271-279
9. Echemann M., Alla F., Briançon S., Juilliere Y., Virion J.M., Mertès P.M., et al., on behalf of EPICAL Investigators. Antithrombotic therapy is associated with better survival in severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 4 (2002) 647-654
10. Malinin A.I., O'Connor C.M., Dzhanashvili A.I., Sane D.C., and Sebruany V.L. Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?. Am Heart J 145 (2003) 397-403
11. Spaulding C., Charbonnier B., Cohen-Solal A., Juilliere Y., Kromer E.P., Benhamda K., et al. Acute haemodynamic interaction of aspirin and ticlodipine with enalapril. Circulation 98 (1998) 757-765
12. Teo K.K., Yusuf S., Pfeffer M., Torp-Pedersen, Kober L., Hall A., et al., for the ACE inhibitor collaborative group. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360 (2002) 1037-1043
13. Guazzi M., Brambilla R., Reina G., Tumminello G., and Guazzi M.D. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: dose-related adverse effect of aspirin. Arch Intern Med 163 (2003) 1574-1579
14. de Groote P., Dagorn J., Soudan B., Lamblin N., McFadden E., and Bauters C. B-type natriuretic peptide and peak oxygen consumption provide independent information for risk stratification in patients with heart failure. J Am Coll Cardiol 43 (2004) 1584-1589
15. Maeda K., Tsutamoto T., Wada A., Hissanga T., and Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832
16. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
17. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al., for the Breathing Not Properly Multinational Study Investigators. Rapid Measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
18. Charpentier J., Luyt C.E., Fulla Y., Vinsonneau C., Cariou A., Grabar S., et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 32 (2004) 660-665
19. Meune, Mahé I., Cohen-Solal A., Levy B.I., Dudoc D., Simoneau G., et al. Comparative effect of aspirin and clopidogrel on arterial function in CHF. Int J Cardiol 106 (2006) 61-66
20. Davie A.P., Love M.P., and McMurray J.J.V. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharmacol Ther 67 (2000) 530-537
21. Galatius S., Wroblewski H., and Kastrup J. Does aspirin treatment influence vascular resistance and fluid filtration in patients with congestive heart failure?. Heart 81 (1999) 330
22. Hall D., Zeitler H., and Rudolph W. Counteraction of the vasodilatator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 360 (1992) 1037-1043
23. Cleland J.G., Findlay I., Jafri S., Sutton G., Falk R., Bulpitt C., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004) 157-164
24. Massie B.M., Krol W.F., Ammon S.E., Armstrong P.W., Cleland J.G., Collins J.F., et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patients characteristics. J Card Fail 10 (2004) 101-112
25. Cleland J.G.F., Ghosh J., Freemantle N., Kaye G.C., Nasir M., Clark A.L., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronization therapy in heart failure. Eur J Heart Fail 6 (2004) 501-508
26. Cokkinos D.V., Haralabopoulos G.C., Kostis J.B., Toutouzas P.K., and for the HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 8 (2006) 428-432
27. Logeart D., Thabut G., Jourdain P., Chavelas C., Beyne P., Beauvais F., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
28. Murdoch D.R., McDonagh T.A., Byrne J., Blue L., Farmer R., Morton J.J., et al. Titration of vasodilatator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the haemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 6pt1 (1999) 1126-1132
29. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
30. Serebruany V.L., Malinin A.I., Jerome S.D., Lowry D.R., Morgan A.W., Sane D.C., et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 146 (2003) 713-720
31. Kindsvaster S., Leclerc K., and Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol 91 (2003) 1350-1352
32. Bruins S., Fokkema M.R., Römer J.W., Dejongste M.J., van der Dijs F.P., van den Ouweland J.M., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 (2004) 2052-2058
33. Peters R.J., Mehta S.R., Fox K.A., Zhao F., Lewis B.S., Kopecky S.L., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
34. Lim E., Ali Z., Ali A., Routledge T., Edmons L., Altman D.G., et al. Indirect comparison meta-analysis of aspirin therapy after surgery. Br Med J 327 (2003) 1309-1314
35. MacIntrye I.M., Jhund P.S., and McMurray J.J.V. Aspirin inhibits the acute and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovasc Drugs Ther 19 (2005) 261-265